| __timestamp | MannKind Corporation | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 581800000 |
| Thursday, January 1, 2015 | 29674000 | 671900000 |
| Friday, January 1, 2016 | 14917000 | 876700000 |
| Sunday, January 1, 2017 | 14118000 | 857900000 |
| Monday, January 1, 2018 | 8737000 | 822200000 |
| Tuesday, January 1, 2019 | 6900000 | 778200000 |
| Wednesday, January 1, 2020 | 6248000 | 512600000 |
| Friday, January 1, 2021 | 12312000 | 681000000 |
| Saturday, January 1, 2022 | 19721000 | 662200000 |
| Sunday, January 1, 2023 | 31283000 | 910700000 |
Data in motion
In the ever-evolving pharmaceutical landscape, innovation is the key to staying ahead. Over the past decade, Viatris Inc. and MannKind Corporation have shown contrasting approaches to research and development (R&D) investments. From 2014 to 2023, Viatris consistently outpaced MannKind, investing nearly 30 times more in R&D on average. In 2023, Viatris allocated approximately $910 million, marking a 77% increase from its 2014 expenditure. Meanwhile, MannKind's R&D spending peaked in 2014 at around $100 million but dwindled to a low of $6 million in 2020, before rebounding to $31 million in 2023. This disparity highlights Viatris's commitment to innovation, while MannKind's fluctuating investments suggest a more cautious approach. As the industry continues to prioritize groundbreaking therapies, these investment trends could shape the future trajectories of both companies.
Research and Development Expenses Breakdown: Eli Lilly and Company vs Viatris Inc.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and MannKind Corporation
Bristol-Myers Squibb Company vs Viatris Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Zoetis Inc. vs MannKind Corporation
Research and Development Investment: Viatris Inc. vs Exelixis, Inc.
Comparing Innovation Spending: Viatris Inc. and Opthea Limited
Research and Development: Comparing Key Metrics for Viatris Inc. and Alpine Immune Sciences, Inc.
Comparing Innovation Spending: Viatris Inc. and CRISPR Therapeutics AG
Viatris Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Intra-Cellular Therapies, Inc. vs MannKind Corporation: Strategic Focus on R&D Spending
R&D Insights: How ImmunityBio, Inc. and MannKind Corporation Allocate Funds
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs MannKind Corporation